Integra LifeSciences Q2 adjusted EPS $0.82 beats prior year; narrows 2022 organic growth guidance to 4.0-5.2%

INTEGRA LIFESCIENCES HOLDINGS CORP

2022-Q2 EPS reported $0.93 revenue$774,453,000

Q2 revenue $398M, +2% reported (+4.8% organic); GAAP EPS $0.54 vs $0.41; adjusted EPS $0.82 vs $0.79.
Full-year 2022 guidance tightened: organic growth 4.0-5.2%; reported revenue $1,557M-$1,575M; adjusted EPS $3.21-$3.29.
Signed agreement to sell non-core traditional wound care business to Gentell for $28.8M; close expected end of August 2022.
Codman Specialty Surgical revenue $257.9M (+4.3% organic); Tissue Technologies revenue $140.0M (+5.9% organic).
Q3 2022 guidance: reported revenue $383M-$391M, organic growth 2.6-4.8%, adjusted EPS $0.78-$0.82.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.